What we do
MarketVIEW: Rotavirus vaccines (June '14)
MarketVIEW: Group B Strep vaccines (May '14)
MarketVIEW: RSV vaccines (Apr '14)
MarketVIEW: Rabies vaccines (Mar '14)
MarketVIEW: Quadrivalent influenza vaccines (Jan '14)
MarketVIEW: Clostridium difficile vaccines (Dec '13)
MarketVIEW: Inactivated polio virus vaccines (Nov '13)
MarketVIEW: Chagas disease vaccines (Nov '13)
MarketVIEW: Cocaine dependence vaccines (July '13)
MarketVIEW: Ross River virus vaccines (July '13)
MarketVIEW: Diabetes vaccines (June '13)
MarketVIEW: Yellow fever vaccines (June '13)
MarketVIEW: Cholesterol vaccines (Mar '13)
MarketVIEW: Smoking cessation vaccines (Mar '13)
MarketVIEW: Hepatitis E virus vaccines (Feb '13)
MarketVIEW: Hepatitis C virus vaccines (Feb '13)
MarketVIEW: Alzheimer's disease vaccines (Jan '13)
MarketVIEW: Hepatitis B virus vaccines (Jan '13)
MarketVIEW: West Nile vaccines (Dec '12)
MarketVIEW: Acne vaccines (Sept '12)
MarketVIEW: Candida vaccines (July '12)
MarketVIEW: HSV TX vaccines (July '12)
MarketVIEW: HAV (Emerging) vaccines (July '12)
MarketVIEW: Quadrivalent influenza vaccines (June '12)
MarketVIEW: S.aureus (Apr '12)
MarketVIEW: Enterovirus-71 (Feb '12)
MarketVIEW: Clostridium difficile (Feb '12)
MarketVIEW: meningococcus serogroup B (Jan '12)
MarketVIEW: universal pneumo (Jan '12)
MarketVIEW: Travelers' diarrhea (Oct '11)
MarketVIEW: JE vaccines (Jan '12)
MarketVIEW: GAS vaccines (June '11)
MarketVIEW: Melanoma vaccines (June '11)
MarketVIEW: Dengue vaccines (Jan '12)
EpibaseID: Global epidemiology database (Oct '11)
MarketVIEW: Lyme Borreliosis vaccines (Nov '10)
VacZine Analytics is an established strategic research consultancy based in the United Kingdom.
We provide high-quality disease and commercial analysis to those working within or in collaboration with the vaccine industry.
Our key focus is helping clients build the case for developing new vaccines
Veterinary vaccines overview
Top ten vaccine industry events - 2015.
Influenza vaccines - more options but don't lose sight of longer term.
No room for blame after our surprise from Ebola.
54th ICAAC, Washington DC conference - selective innovation won't do!
Pfizer vaccines boosts presence with low risk Baxter acquisitions.
Caribbean Chikungunya outbreak should move vaccine back onto the agenda.
Novartis to the vaccines industry - can we have our money back please?
Bexsero®: good for UK children, Novartis Vaccines and a flat industry.
H7N9, like H5N1 - re-exposes weaknesses in pandemic vaccine development
2013 FY results - QIVs: a highlight in a flat industry.
Tweets by @VacZineAnalytic
© 2013 VacZine Analytics. All rights reserved.
Terms and conditions
We sponsor Group B Strep Support.